New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
17:08 EDTSNYSanofi Pastuer annnounces positive results from trial of Fluzone
Sanofi Pasteur, the vaccines division of Sanofi, announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone High-Dose was more efficacious in preventing influenza in adults 65 years of age and older compared to standard-dose Fluzone vaccine. Fluzone High-Dose vaccine was found to be 24.2% (95% CI, 9.7 to 36.5) more effective in preventing influenza relative to standard-dose Fluzone vaccine for the primary endpoint, indicating that about one in four breakthrough cases of influenza could be prevented if Fluzone High-Dose vaccine were used instead of the standard-dose Fluzone vaccine in this population. Additionally, relative efficacy was 35.4% (95% CI, 12.5 to 52.5) in an analysis restricted to influenza cases caused by vaccine-similar strains. Fluzone High-Dose vaccine is an inactivated influenza vaccine that contains four times the amount of antigen than is contained in standard-dose Fluzone vaccine and induces a higher antibody response.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
06:34 EDTSNYImmunoGen appoints Richard Gregory as Chief Scientific Officer
ImmunoGen (IMGN) announced the appointment of Richard Gregory as Executive Vice President, Research and Chief Scientific Officer. Gregory will join the company on January 5, 2015, at which time current CSO, John Lambert, will assume the position of Executive Vice President, Distinguished Research Fellow. Gregory most recently served as senior vice president and head of research for the Sanofi (SNY) Genzyme Research & Development Center.
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use